NCT01108393

Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder

Efficacy of Agomelatine 25mg/Day (With Possible Increase to 50mg/Day After 8 Weeks of Treatment) Given Orally During 16 Weeks in Patients With Obsessive-Compulsive Disorder. A Randomised, Double-blind, Placebo-controlled, Parallel Groups, International Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Institut de Recherches Internationales Servier · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study will evaluate the efficacy of agomelatine compared to placebo on the reduction of Obsessive and Compulsive symptoms after 16 weeks of treatment.

Conditions

• Obsessive Compulsive Disorder

Interventions

Type	Name	Description
DRUG	Agomelatine A	Agomelatine 25 mg film-coated tablet Agomelatine 2x25mg film-coated tablet
DRUG	Placebo	Placebo

Timeline

• Start date: 2010-05-01
• Primary completion: 2012-08-01
• Completion: 2013-04-01
• First posted: 2010-04-22
• Last updated: 2024-07-25

Locations

1 site across 1 country: Israel